Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes

Autor: Akvile Statnickaite, Kristina Jureniene, Jorune Suipyte, Sigita Liutkauskiene, Elona Juozaityte, Saulius Grizas
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Oncology
Cancer Research
medicine.medical_specialty
Cyclophosphamide
Anthracycline
Molecular subtypes
medicine.medical_treatment
Breast Neoplasms
Kaplan-Meier Estimate
Neutropenia
lcsh:RC254-282
Time-to-Treatment
03 medical and health sciences
0302 clinical medicine
Breast cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Genetics
Medicine
Humans
Doxorubicin
Anthracyclines
Overall survival
030212 general & internal medicine
Neoplasm Staging
Proportional Hazards Models
Retrospective Studies
Chemotherapy
Chemotherapy scheme modifications
business.industry
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
AC Regimen
Combined Modality Therapy
Regimen
Treatment Outcome
030220 oncology & carcinogenesis
Female
Neoplasm Grading
business
medicine.drug
Research Article
Zdroj: BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Cancer
ISSN: 1471-2407
DOI: 10.1186/s12885-018-4365-y
Popis: Background The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons for such chemotherapy scheme modifications. Methods Medical records of patients with stage I-III breast cancer were reviewed. Inclusion criteria involved stage I- III breast carcinoma; radical surgery performed and 4 courses of AC regimen (doxorubicin and cyclophosphamide), or at least 6 courses of FAC regimen (fluorouracil, doxorubicin and cyclophosphamide) completed; no neoadjuvant chemotherapy applied; no taxane group medications administered; medical records maintain comprehensive data on treatment and follow-up. 5- year overall survival were analyzed using Kaplan-Meier and Cox proportional hazards models. Results Significant 3.17 times higher death risk at 5 year period in patients who experienced anthracycline dose reduction compared with patients who did not experience any modifications was established (HR = 3.17, 95% CI 1.7–5.9, p
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje